Orforglipron vs Rybelsus | Research Comparison | QSC

Orforglipron vs Rybelsus: Research Comparison

Mechanism, clinical data, and research applications compared

Shop Both Compounds at QSC →

Factor Orforglipron Rybelsus
Drug Class Non-peptide GLP-1R agonist Oral semaglutide (peptide + SNAC)
Route Oral once-daily SC weekly / oral
Phase 2/3 Result −14.7% (36 wks)* ~5-7% weight loss
At QSC ✓ In Stock ✓ In Stock
Research Analysis: Orforglipron: no food restrictions, higher Phase 2 efficacy. Rybelsus: approved, established.
Research Use Only: All QSC products for in vitro laboratory research only. Not for human use.
Peptides
Orals
Oils
Search
Contact